Randomized, Double-Blind, Placebo-Controlled Phase Ii Trial Of Low-Dose Metronomic Cyclophosphamide Alone Or In Combination With Veliparib (Abt-888) In Chemotherapy-Resistant Er And/Or Pr-Positive, Her2/Neu-Negative Metastatic Breast Cancer: New York Cancer Consortium Trial P8853.